Skip to main content
. 2021 May 31;13(6):e14062. doi: 10.15252/emmm.202114062

Table 6.

India.

(A) 01/27–05/27/2020* 06/03–07.04.2020
Position Location Mutation Count Count Incidence
241nt 5´UTR CG → TG 82/99 95/98 Prevalent
noneffective
2,292nt nsp2 AG → CG 0/99 22/98 Unique
CAG (Glutamine) → CCG (Proline)
2,836nt nsp3 CT → TT 23/99 44/98 Unique
noneffective
3,037nt CT → TT 81/99 96/98 Prevalent
noneffective
3,634nt CA → TA 8/99 17/98 ZA
noneffective
4,084nt CA → TA 12/99 1/98 ZA
noneffective
4,300nt GC → TC 0/99 16/98 Unique
noneffective
6,312nt CA → AA 10/99 0/98 US
ACA (Threonine) → AAA (Lysine)
11,083nt nsp6 GT → TT 13/99 0/98 BR,CN,DE,
TTGTAT (Leucine Tyrosine) → TTT (Phenylalanine) ES,FR,US,
ZA
14,408nt RNA‐dependent RNA polymerase CT → TT 80/99 91/98 Prevalent
CCT (Proline) → CTT (Leucine)
15,324nt CA → TA 7/99 18/98 B,C,G,F
noneffective
16,512nt Helicase AT → GT 0/99 11/98 Unique
noneffective
18,568nt 3´‐ to ‐ 5´exonuclease CT → TT 0/99 22/98 Unique
CTC (Leucine) → TTC (Phenylalanine)
18,877nt CT → TT 45/99 51/98 BR,DE,ES,
noneffective FR,US
19,154nt CA → TA 0/99 12/98 Unique
ACA (Threonine) → ATA (Isoleucine)
21,724nt Spike glycoprotein GT → TT 6/99 23/98 RU
TTGTTC (Leucine Phenylalanine) → TTTTTC (Phenylalanine Phenylalanine)
22,444nt CC → TC 26/99 48/98 US
noneffective
23,403nt AT → GT 80/99 96/98 Prevalent
GAT (Aspartic Acid) → GGT (Glycine)
23,929nt CA → TA 10/99 0/98 FR,RU,US
noneffective
25,563nt ORF3a protein GA → TA 43/99 51/98 Prevalent
CAGAGC (Glutamine Serine) → CATAGC (Histidine Serine)
26,735nt Membrane glycoprotein CA → TA 39/99 49/98 DE,ES,FR,
noneffective US
28,311nt Nucleocapsid phosphoprotein CC → TC 10/99 0/98 Unique
CCC (Proline) → CTC (Leucine)
28,854nt CA → TA 29/99 41/98 CN,DE,ES,
TCA (Serine) → TTA (Leucine) FR,RU,US,
ZA
(B) 01/19/2020–01/20/2021
Position Location Mutation Total Count Percentage
241nt 5´UTR C → T 2,816 85.93
313nt ORF1ab polyprotein → leader protein C → T 944 28.81
1,947nt nsp2 T → C 100 3.05
2,292nt A → C 73 2.23
2,836nt nsp3 C → T 281 8.57
3,037nt C → T 2,824 86.18
3,634nt C → T 283 8.64
4,300nt G → T 70 2.14
4,354nt G → A 227 6.93
4,372nt A → G 72 2.2
5,700nt C → A 949 28.96
6,312nt C → A 302 9.22
6,573nt C → T 228 6.96
8,782nt nsp4 C → T 74 2.26
8,917nt C → T 122 3.72
9,693nt C → T 156 4.76
11,083nt nsp6 G → T 369 11.26
13,730nt RNA‐dependent RNA polymerase C → T 332 10.13
14,408nt C → T 2,768 84.47
15,324nt C → T 285 8.7
16,626nt Helicase C → T 143 4.36
18,568nt 3'‐to‐5' exonuclease C → T 71 2.17
18,877nt C → T 654 19.96
19,524nt C → T 69 2.11
21,550nt 2'‐O‐ribose methyltransferase A → C 115 3.51
21,551nt A → T 112 3.42
21,724nt Spike glycoprotein G → T 109 3.33
22,444nt C → T 507 15.47
22,468nt G → T 76 2.32
23,403nt A → G 2,832 86.42
23,929nt C → T 298 9.09
25,528nt ORF3a C → T 222 6.77
25,563nt G → T 652 19.9
26,735nt Membrane glycoprotein C → T 654 19.96
27,384nt ORF6 T → C 77 2.35
28,144nt ORF8 T → C 73 2.23
28,311nt Nucleocapsid phosphoprotein C → T 299 9.12
28,854nt C → T 541 16.51
28,878nt G → A 70 2.14
28,881nt G → A 1,434 43.76
28,882nt G → A 1,430 43.64
28,883nt G → C 1,430 43.64
29,474nt G → T 72 2.2
29,750nt 3´UTR C → T 74 2.26
29,868nt at downstream region of ORF10 G → A 351 10.71
29,870nt C → A 154 4.7

The Table presents characteristics of SARS‐CoV‐2 mutants from isolates collected in the Indian population. For Table design, see legend to Table 5.